azepan-1-yl-(5-piperidin-3-yl-thiophen-3-yl)-methanone | 1160718-79-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: azepan-1-yl-(5-piperidin-3-yl-thiophen-3-yl)-methanone
• 英文别名: azepan-1-yl-(5-piperidin-3-ylthiophen-3-yl)methanone
• CAS: 1160718-79-5
• 化学式: C₁₆H₂₄N₂OS
• 分子量: 292.445
• InChiKey: SMARZSYEOUWYJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  60.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-[4-(azepane-1-carbonyl)-thiophen-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 在 二氯甲烷 、 甲醇 、 乙腈 、 desired compound 、 氨 作用下， 以 trifluoracetic acid-dichloromethane 为溶剂， 反应 1.0h， 以gave the title compound as a clear colourless oil (0.052 g)的产率得到azepan-1-yl-(5-piperidin-3-yl-thiophen-3-yl)-methanone
  参考文献：
  名称：

  Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors

  摘要：

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，它们可以抑制11β-羟基类固醇脱氢酶类型1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物在体内外抑制11β-羟基类固醇脱氢酶类型1；治疗通过抑制11β-羟基类固醇脱氢酶类型1改善的疾病；治疗代谢综合症，包括2型糖尿病和肥胖症，以及相关疾病，包括胰岛素抵抗、高血压、脂质代谢异常和缺血性（冠状动脉）心脏疾病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆症，包括阿尔茨海默病等。

  公开号：

  US08362008B2

文献信息

• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BÊTA-HSD1
  申请人：UNIV EDINBURGH

  公开号：WO2009074789A1

  公开（公告）日：2009-06-18

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. Formula (I).

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。公式（I）。
• Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors
  申请人：Webster Scott Peter

  公开号：US20100267696A1

  公开（公告）日：2010-10-21

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1型（11β-HSD1）的化合物。本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制11β-羟基类固醇脱氢酶1型，治疗通过抑制11β-羟基类固醇脱氢酶1型改善的疾病，治疗代谢综合征，包括2型糖尿病和肥胖症，以及相关疾病，包括胰岛素抵抗、高血压、脂质异常和缺血性（冠状动脉）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。
• AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS
  申请人：THE UNIVERSITY OF EDINBURGH

  公开号：EP2229374A1

  公开（公告）日：2010-09-22
• US8362008B2
  申请人：——

  公开号：US8362008B2

  公开（公告）日：2013-01-29
• Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors
  申请人：Webster Scott Peter

  公开号：US08362008B2

  公开（公告）日：2013-01-29

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，它们可以抑制11β-羟基类固醇脱氢酶类型1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物在体内外抑制11β-羟基类固醇脱氢酶类型1；治疗通过抑制11β-羟基类固醇脱氢酶类型1改善的疾病；治疗代谢综合症，包括2型糖尿病和肥胖症，以及相关疾病，包括胰岛素抵抗、高血压、脂质代谢异常和缺血性（冠状动脉）心脏疾病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆症，包括阿尔茨海默病等。